Andrew Armstrong

Professor

Duke Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Andrew Armstrong is based at the Duke Cancer Institute in the United States. His research focuses on prostate cancer, particularly in areas such as homologous repair deficiency testing, therapeutic sequencing, and the clinical outcomes of patients receiving various treatments. He has published extensively on the implications of genetic testing and evidence-based strategies for managing advanced prostate cancer.

Articles (22)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (16)

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES

Andrew Armstrong

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey

Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)

Reply to: Recalibrating Digital Predictions: Uncovering the Limits of the MMAI Prostate LT-ADT Predictive Model in the Era of Tumor Evolution

Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy

Implementing evidence‐based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)

Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial

The Past, Present, and Future of Treatment Intensification for Metastatic Hormone–Sensitive Prostate Cancer

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

Germline Testing in Prostate Cancer: Implementation and Disparities of Care

Relationship Between Pretreatment Body Composition and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Ipilimumab Plus Nivolumab

Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance

Reply to E. Hindié

Collaborators (16)

Joshua Lang

Scott Tagawa

Alicia Morgans

Kim Chi

Tae Min Kim

Jason Somarelli

Alan Haruo Bryce

Susan Halabi

Irenaeus Chan

Brian Miller

Emmanuel Stylianos Antonarakis

Qianben Wang

Todd Druley

Kevin Kelly

Jae Lyun Lee

Qing Yang

Make your next move.